Suppr超能文献

长期双膦酸盐治疗对小梁骨强度和微裂纹密度的影响。

The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density.

作者信息

Jin A, Cobb J, Hansen U, Bhattacharya R, Reinhard C, Vo N, Atwood R, Li J, Karunaratne A, Wiles C, Abel R

机构信息

Department of Mechanical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.

Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK.

出版信息

Bone Joint Res. 2017 Oct;6(10):602-609. doi: 10.1302/2046-3758.610.BJR-2016-0321.R1.

Abstract

OBJECTIVES

Bisphosphonates (BP) are the first-line treatment for preventing fragility fractures. However, concern regarding their efficacy is growing because bisphosphonate is associated with over-suppression of remodelling and accumulation of microcracks. While dual-energy X-ray absorptiometry (DXA) scanning may show a gain in bone density, the impact of this class of drug on mechanical properties remains unclear. We therefore sought to quantify the mechanical strength of bone treated with BP (oral alendronate), and correlate data with the microarchitecture and density of microcracks in comparison with untreated controls.

METHODS

Trabecular bone from hip fracture patients treated with BP (n = 10) was compared with naïve fractured (n = 14) and non-fractured controls (n = 6). Trabecular cores were synchrotron scanned and micro-CT scanned for microstructural analysis, including quantification of bone volume fraction, microarchitecture and microcracks. The specimens were then mechanically tested in compression.

RESULTS

BP bone was 28% lower in strength than untreated hip fracture bone, and 48% lower in strength than non-fractured control bone (4.6 MPa 6.4 MPa 8.9 MPa). BP-treated bone had 24% more microcracks than naïve fractured bone and 51% more than non-fractured control (8.12/cm 6.55/cm 5.25/cm). BP and naïve fracture bone exhibited similar trabecular microarchitecture, with significantly lower bone volume fraction and connectivity than non-fractured controls.

CONCLUSION

BP therapy had no detectable mechanical benefit in the specimens examined. Instead, its use was associated with substantially reduced bone strength. This low strength may be due to the greater accumulation of microcracks and a lack of any discernible improvement in bone volume or microarchitecture. This preliminary study suggests that the clinical impact of BP-induced microcrack accumulation may be significant.: A. Jin, J. Cobb, U. Hansen, R. Bhattacharya, C. Reinhard, N. Vo, R. Atwood, J. Li, A. Karunaratne, C. Wiles, R. Abel. The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density. 2017;6:602-609. DOI: 10.1302/2046-3758.610.BJR-2016-0321.R1.

摘要

目的

双膦酸盐(BP)是预防脆性骨折的一线治疗药物。然而,由于双膦酸盐与骨重塑过度抑制和微裂纹积累有关,人们对其疗效的担忧日益增加。虽然双能X线吸收法(DXA)扫描可能显示骨密度增加,但这类药物对力学性能的影响仍不清楚。因此,我们试图量化用BP(口服阿仑膦酸盐)治疗的骨骼的力学强度,并将数据与未治疗的对照组相比的微结构和微裂纹密度相关联。

方法

将接受BP治疗的髋部骨折患者(n = 10)的小梁骨与初次骨折患者(n = 14)和未骨折对照组(n = 6)进行比较。对小梁骨芯进行同步加速器扫描和显微CT扫描以进行微观结构分析,包括骨体积分数、微结构和微裂纹的量化。然后对标本进行压缩力学测试。

结果

BP治疗的骨骼强度比未治疗的髋部骨折骨骼低28%,比未骨折对照组骨骼低48%(4.6兆帕 6.4兆帕 8.9兆帕)。BP治疗的骨骼比初次骨折骨骼的微裂纹多24%,比未骨折对照组多51%(8.12/厘米 6.55/厘米 5.25/厘米)。BP治疗组和初次骨折组的小梁微结构相似,骨体积分数和连通性均显著低于未骨折对照组。

结论

在所检查的标本中,BP治疗未显示出可检测到的力学益处。相反,其使用与骨强度大幅降低有关。这种低强度可能是由于微裂纹积累更多以及骨体积或微结构缺乏任何明显改善。这项初步研究表明,BP诱导的微裂纹积累对临床的影响可能很大。:A. 金、J. 科布、U. 汉森、R. 巴塔查里亚、C. 莱因哈德、N. 沃、R. 阿特伍德、J. 李、A. 卡鲁纳拉特内、C. 怀尔斯、R. 阿贝尔。长期双膦酸盐治疗对小梁骨强度和微裂纹密度的影响。2017年;6:602 - 609。DOI:10.1302/2046 - 3758.610.BJR - 2016 - 0321.R1

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a062/5670367/021e542cc770/bonejointres-06-602-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验